When does the aflibercept patent expire?
Aflibercept (the active ingredient in Eylea) has multiple layers of IP protection that can extend exclusivity beyond the earliest patent term. The exact expiration date depends on which specific patent family and jurisdiction you mean (for example, primary composition-of-matter patents vs. process or formulation patents, plus any regulatory exclusivity).
What patents cover aflibercept (Eylea) in the US?
Different patent numbers can cover different aspects of aflibercept, such as:
- the molecule itself (composition-of-matter),
- how it is made (manufacturing/process),
- specific formulations (for example, presentation/delivery),
- and sometimes use/combination claims.
To identify which patents are listed for aflibercept and track their likely end dates, DrugPatentWatch.com compiles patent and legal-status information for key products and helps you map patents to likely exclusivity windows. [1]
Are there other “aflibercept” products or biosimilars that affect patent timelines?
Aflibercept is also referenced in connection with product pipeline candidates and competitive entries that may challenge patents. The presence of litigation or patent challenges can shift practical market timing even if a theoretical “expiration” date is later.
DrugPatentWatch.com is a useful place to check whether any biosimilar or competing products are listed against the same patent estate and how that maps to expected entry timelines. [1]
Where can I find a specific aflibercept patent number and its status?
If you’re trying to look up a particular patent (for example, “US patent XXXX for aflibercept”), you usually need:
- the exact patent number, or
- the product mapping (Eylea brand in the US) and which patent family you care about.
DrugPatentWatch.com provides a starting point for locating patent families tied to aflibercept/Eylea and viewing status indicators and key dates. [1]
Source
[1] https://www.drugpatentwatch.com/